Skip to content

Pessary or surgery for symptomatic pelvic organ prolapse

Pessary or surgery for symptomatic pelvic organ prolapse - PEOPLE - PEssary Or ProLapse surgEry

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON47134
Enrollment
436
Registered
2014-11-25
Start date
2015-03-23
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolapse

Interventions

Pessary therapy or POP surgery

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Women with a prolapse stage 2 or more. 2. Women with moderate to severe POP symptoms. Moderate to severe POP symptoms is defined as a prolapse domain score > 33 on the validated Dutch version of the Pelvic Floor Distress Inventory (PFDI-20). 3. Women who have had a successful pessary fitting procedure: for the RCT. 4. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Prior urogynaecological (prolapse or incontinence) surgery 2. Probability of future childbearing 3. Insufficient knowledge of the Dutch language 4. Co-morbidity causing increased surgical risks 5. Major psychiatric illness 6. Prior pessary use

Design outcomes

Primary

MeasureTime frame
Primary outcome: Global impression of improvement of POP symptoms at 24 months measured with PGI-I

Secondary

MeasureTime frame
Secondary outcomes: * Changes in symptom bother and disease-specific quality of life at 12 and 24 months follow-up * Changes of sexual function at 12 and 24 months follow-up * Changes in general quality of life at 3, 6, 12 and 24 months. * Adverse events/complications related to both treatment strategies during the study period * Development of prediction model to identify factors for failing of pessary and surgery. * Costs-effectiveness analyses

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)